mProX™ Human RPS6KA2 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

RPS6KA2, also known as ribosomal protein S6 kinase A2, has been studied in various contexts. In ovarian cancer, RPS6KA2 is involved in cuproptosis, a form of programmed cell death, and its related long non-coding RNAs (lncRNAs) have been characterized. These lncRNAs have been used to define molecular subtypes of ovarian cancer and establish a prognostic signature that can predict survival time, immune characteristics, and response to therapy. In Crohn's disease, RPS6KA2 is associated with DNA methylation alterations that may predict disease recurrence following intestinal resection. In knee osteoarthritis, RPS6KA2 enhances the chondrogenic differentiation of induced mesenchymal stem cells (iMSCs), leading to articular cartilage regeneration. In Yorkshire pigs, RPS6KA2 is one of the candidate genes identified in a genome-wide association study on reproductive traits. Finally, in food allergy, epigenome-wide association studies have found DNA methylome variations in RPS6KA2 and other genes associated with immune responses and regulatory T cell function. These findings provide insights into the role of RPS6KA2 in different diseases and highlight its potential as a therapeutic target or biomarker.